Wang Yi-Ya, Shen Xiao-Hang, Li Hao, Chen Feng-Ju, Fu Yan, Ding Li
Department of Pharmaceutical Analysis, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China.
Bioanalytical Service, WuXi AppTec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China.
J Pharm Anal. 2013 Aug;3(4):221-228. doi: 10.1016/j.jpha.2012.12.002. Epub 2013 Jan 4.
A sensitive, simple and rapid high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was developed and fully validated for the simultaneous quantification of buprenorphine (BUP) and its N-dealkylated metabolite norbuprenorphine (NBUP) in 200 μL human plasma. Human plasma samples were prepared using liquid-liquid extraction, and then separated on a Shiseido MG C18 (5 μm, 2.0 mm×50 mm) via 4.1 min gradient elution. Following electrospray ionization, the analytes were quantified on a triple-quadrupole mass spectrometer in multiple-reaction-monitoring (MRM) positive ion mode. Linearity was achieved from 25.0 to 10000 pg/mL for buprenorphine, from 20.0 to 8000 pg/mL for norbuprenorphine with >0.99. The method was demonstrated with acceptable accuracy, precision and specificity for the detection of buprenorphine and norbuprenorphine. Recovery was 81.8-88.8% for buprenorphine and 77.0-84.6% for norbuprenorphine, and the matrix effect was 95.6-97.4% for buprenorphine and 94.0-96.9% for norbuprenorphine; all were not concentration dependent. With validated matrix and autosampler stability data, this method was successfully applied in a bioequivalence study to support abbreviated new drug application.
建立了一种灵敏、简便、快速的高效液相色谱-串联质谱(HPLC-MS/MS)方法,并对其进行了全面验证,用于同时定量200μL人血浆中的丁丙诺啡(BUP)及其N-脱烷基代谢物去甲丁丙诺啡(NBUP)。人血浆样品采用液-液萃取法制备,然后在资生堂MG C18(5μm,2.0mm×50mm)柱上通过4.1分钟梯度洗脱进行分离。经电喷雾电离后,在三重四极杆质谱仪上以多反应监测(MRM)正离子模式对分析物进行定量。丁丙诺啡的线性范围为25.0至10000pg/mL,去甲丁丙诺啡的线性范围为20.0至8000pg/mL,相关系数>0.99。该方法在检测丁丙诺啡和去甲丁丙诺啡时具有可接受的准确度、精密度和特异性。丁丙诺啡的回收率为81.8-88.8%,去甲丁丙诺啡的回收率为77.0-84.6%,丁丙诺啡的基质效应为95.6-97.4%,去甲丁丙诺啡的基质效应为94.0-96.9%;均不依赖浓度。凭借经过验证的基质和自动进样器稳定性数据,该方法成功应用于生物等效性研究,以支持简略新药申请。